

their tissue inhibitors in patients with small-cell lung cancer. *Journal of clinical oncology*, 17(6), 1802-1802.

Minucci, S., & Pelicci, P. G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. *Nature Reviews Cancer*, 6(1), 38-51.

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., ... & Fukuoka, M. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *The lancet oncology*, 11(2), 121-128.

Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., & Olson, A. J. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *Journal of computational chemistry*, 19(14), 1639-1662.

Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of computational chemistry*, 30(16), 2785-2791.

Moses, M. A., & Langer, R. (1991). A metalloproteinase inhibitor as an inhibitor of neovascularization. *Journal of cellular biochemistry*, 47(3), 230-235.

Moses, M. A., Sudhalter, J., & Langer, R. (1990). Identification of an inhibitor of neovascularization from cartilage. *Science*, 248(4961), 1408-1410.

Nelson W. G., De Marzo A. M., Isaacs W. B. (2003). Prostate cancer. *The New England Journal of Medicine*, 349(4), 366–381.